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Toll-like receptor 9 (TLR9), its adaptor MyD88, the
downstream transcription factor interferon regulato-
ry factor 7 (IRF7), and type I interferons (IFN-I) are all
required for resistance to infectionwith ectromelia vi-
rus (ECTV). However, it is not known how or in which
cells these effectors function to promote survival.
Here, we showed that after infection with ECTV,
the TLR9-MyD88-IRF7 pathway was necessary in
CD11c+ cells for the expression of proinflammatory
cytokines and the recruitment of inflammatorymono-
cytes (iMos) to the draining lymph node (dLN). In the
dLN, the major producers of IFN-I were infected
iMos, which used the DNA sensor-adaptor STING
to activate IRF7 and nuclear factor kB (NF-kB)
signaling to induce the expression of IFN-a and
IFN-b, respectively. Thus, in vivo, two pathways of
DNA pathogen sensing act sequentially in two
distinct cell types to orchestrate resistance to a viral
disease.
INTRODUCTION
The ability of the innate immune system to sense infection is
essential to mount innate and adaptive immune responses (Iwa-
saki and Medzhitov, 2010; Wu and Chen, 2014). It is well estab-
lished that pathogen recognition receptors (PRRs) recognize
pathogen-associated molecular patterns (PAMPs) to activate
innate immune signaling pathways (Iwasaki and Medzhitov,
2010). PAMPs are typically microbial nucleic acids and other
macromolecules with repetitive structures common to patho-
gens but not usually encountered in uninfected cells (Schenten
and Medzhitov, 2011). PRR-initiated signaling cascades after
virus infection culminate in the expression of type I interferon
(IFN-I), pro-inflammatory cytokines, and chemokines that recruit1148 Immunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inand activate innate and adaptive immune cells (Wu and Chen,
2014).
PAMPs in the cell microenvironment are recognized by
transmembrane PRRs that reside in the plasma and endosomal
membranes, such as Toll-like receptors (TLRs)—for example,
TLR9 recognizes double-stranded DNA in endosomes (Ah-
mad-Nejad et al., 2002; Hemmi et al., 2000). PAMPs in the
cytosol, on the other hand, are sensed by cytosolic PRRs—for
instance, RIG-I-like receptors (RLRs) detect cytosolic viral RNA
species (Goubau et al., 2013; Vabret and Blander, 2013),
whereas DNA-dependent activator of IFN-regulatory factors
(DAI), interferon-activated gene 204 (Ifi204, IFI16 in humans),
and cyclic-GMP-AMP (cGAMP) synthase (cGAS, encoded by
M21d1) respond to cytosolic DNA (Wu and Chen, 2014).
Tosignal, PRRsuseadapters.Theadapters forTLRsareMyD88
and TIR-domain-containing adaptor-inducing IFN-b (TRIF); for
RLRs, mitochondrial antiviral-signaling protein (MAVS); and for
DNA-sensing PRRs, STING (Wu and Chen, 2014). Additional
signaling steps downstream of these adapters link PRRs to the
activation of several transcription factors, most frequently IRF3,
IRF7, and NF-kB. These transcription factors induce the expres-
sion of IFN-I and pro-inflammatory cytokines (Wu and Chen,
2014).
Soon after breaching epithelia, many pathogenic viruses
rapidly spread through afferent lymphatics to the regional drain-
ing lymph nodes (dLNs), from where they disseminate through
efferent lymphatics to the bloodstream, ultimately reaching their
target organs (Flint et al., 2009; Virgin, 2007). Ectromelia virus, an
Orthopoxvirus (a genus of large DNA viruses), is the causative
agent of mousepox, themouse homolog of human smallpox (Es-
teban and Buller, 2005). After infection through the skin of the
footpad, ECTV spreads lympho-hematogenously to cause sys-
temic disease. Indeed, ECTV was the virus used to describe
this form of dissemination (Fenner, 1948) and is used as the text-
book paradigm of lympho-hematogenous spread (Flint et al.,
2009; Virgin, 2007).
During lympho-hematogenous dissemination, a swift anti-viral
innate response in the dLN can play a major role in restrictingc.
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Figure 1. TLR9, MyD88, and STING Are Critical for Resistance to Mousepox and the Efficient Induction of IFN-I in Lymph Nodes
Mice were infected with 3,000 PFUs of ECTV in the footpad.
(A) Survival of the indicated mice.
(B) Virus loads in the livers of the indicated mice at 7 dpi as determined by plaque assay.
(C) Liver sections of the indicated mice at 7 dpi stained with H&E (top) or immunostained with anti-ECTV Ab (bottom).
(D) Expression of IFN-I in the dLNs of the indicated mice at 2.5 dpi as determined by RT-qPCR.
(E) Survival of the indicated mice.
(F) Expression of IFN-I in the dLNs of the indicated mice at 2.5 dpi as determined by RT-qPCR.
Data are shown either as individual mice with mean ± SEM or as mean ± SEM. Each panel displays data from one experiment with five mice per group and is
representative of three similar experiments. For all, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.viral spread and deterring disease (Fang et al., 2008; Junt et al.,
2007; Kastenmu¨ller et al., 2012). It is therefore important to un-
derstand how different mechanisms of virus sensing contribute
to this process. Here we dissect the contribution of PRRs to
the antiviral response to ECTV in the dLN. We show that the
TLR9-MyD88-IRF7 axis is necessary in CD11c+ cells for the che-
mokine-driven recruitment of inflammatory monocytes (iMos) to
the dLN, but not directly essential for IFN-I production. Once
iMos are infected, they use STING-IRF7 and STING-NF-kB path-
ways to induce the expression of IFN-a and IFN-b, respectively.
Collectively, our work shows that the TLR9-MyD88-IRF7 and
STING-IRF7 or STING-NF-kB pathways have non-redundant,
complementary, and sequential roles in IFN-I expression in the
dLNs and in resistance to a highly pathogenic viral disease.
RESULTS
TLR9-MyD88 and STING Are Critical for Resistance to
Mousepox and the Efficient Induction of IFN-I in Lymph
Nodes
The TLR adaptor MyD88 is required for the inherent resistance of
B6 mice to mousepox (Rubio et al., 2013; Sutherland et al.,
2011), whereas TRIF is not necessary (data not shown). We per-
formed experiments to identify the specific role of MyD88, asImmwell as of MAVS- and STING-driven pathways, in resistance
to mousepox and IFN-I expression in vivo during acute ECTV
infection. We found that after infection with ECTV in the footpad,
mice deficient in MyD88 (Myd88/) or with inactive STING
(Tmem173gt), but not those lacking MAVS (Mavs/), were sus-
ceptible to lethal mousepox (Figure 1A). Nevertheless, death
occurred in 100% of Myd88/ but in only 80% Tmem173gt
mice, a difference that was reproducible and highly significant
(p < 0.0001) suggesting a more profound impairment in the
absence of MyD88 than in the absence of STING signaling.
Consistently, virus loads (Figure 1B) and pathology (Figure 1C)
in the livers of Myd88/ and Tmem173gt, but not of Mavs/,
mice were significantly higher than in B6 mice. Notably, the virus
titers were significantly lower (p < 0.01) and the liver pathology
was somewhat milder in Tmem173gt than in Myd88/ mice.
We next performed reverse transcriptase quantitative polymer-
ase chain reaction (RT-qPCR) on RNA obtained from the dLNs
at 2.5 days post infection (dpi). We found that Myd88/ and
Tmem173gt but not Mavs/ mice expressed significantly lower
levels of ‘‘early’’ IFN-b and ‘‘late’’ IFN-a5 than B6mice. However,
Myd88/mice expressed significantly lower levels of IFN-b (p <
0.0001) and IFN-a5 (p < 0.0001) than Tmem173gt mice (Fig-
ure 1D). Thus, MyD88 and STING, but notMAVS, are both critical
adapters for resistance to lethal ECTV infection and the efficientunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inc. 1149
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Figure 2. IFN-I Expression Requires MyD88 and STING in Bone-
Marrow-Derived Cells
Mice were infected with 3,000 PFUs of ECTV in the footpad.
(A) Expression of IFN-I in the dLNs of the indicated bone marrow chimeras at
2.5 dpi.
(B) Expression of IFN-I in the dLNs of the indicatedmice at 2.5 dpi. p values are
compared to Vav1-Cre- Myd88fl/fl.
(C) Survival of indicated mice.
When applicable, data are shown as mean ± SEM. Each panel displays data
from one experiment with five mice per group and is representative of three
similar experiments except for (A), which was performed twice. For all, *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.expression of IFN-I in the dLNs in vivo. However, mice are signif-
icantly more susceptible to mousepox with absent MyD88 than
with deficient STING.
Next, we investigated several molecules upstream of MyD88
and STING that could be required for resistance to mousepox
and/or IFN-I expression in the dLNs. As before, mice deficient
in TLR9 (Tlr9/), but not in other TLRs, were susceptible to
mousepox (Rubio et al., 2013; Samuelsson et al., 2008; Suther-
land et al., 2011). In contrast, mice deficient in the IL-1 receptor
(Il1r/), which also uses MyD88 as its adaptor (Muzio et al.,
1997), and mice deficient in the cytosolic DNA sensor DAI
(Zbp1/) (Ishii et al., 2008), which is thought to signal through
STING, were resistant (Figure 1E and not shown). Moreover, at
2.5 dpi, mice deficient in TLR9, but not in TLR2, IL-1R, or DAI, ex-
pressed significantly lower IFN-I in the dLNs than B6 mice (Fig-
ure 1F and not shown). Thus, among those we tested, the only
PRR upstream of MyD88 that is required for IFN-I expression
in the dLNs during ECTV infection is TLR9. Further, DAI is not
the critical sensor for STING.
IFN-I Expression Requires MyD88 and STING in
Bone-Marrow-Derived Cells
Next, we sought to identify the cells that produce IFN-I during
infection. To distinguish the role of bone-marrow-derived
versus parenchymal cells, we used bone marrow chimeras.
Expression of IFN-b and IFN-a5 in the dLNs at 2.5 dpi was signif-1150 Immunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inicantly lower in Myd88//B6 and Tmem173gt/B6 than in
B6/B6 chimeras. Expression of IFN-b and IFN-a5 was also
significantly lower (p < 0.05 for IFN-b and p < 0.01 for IFN-a5)
inMyd88//B6 than in Tmem173gt/B6 chimeras (Figure 2A).
In another approach, Vav1-Cre+ Myd88fl/fl mice, which specif-
ically lack MyD88 in hematopoietic cells, expressed significantly
less IFN-I than Vav1-Cre Myd88fl/fl controls (Figure 2B). More-
over,Vav1-Cre+Myd88fl/fl but not Vav1-CreMyd88fl/fl mice suc-
cumbed to mousepox with similar kinetics to constitutive
Myd88/ mice (Figure 2C). Consequently, both MyD88 and
STING in bone-marrow-derived cells are essential for the effi-
cient expression of IFN-I during ECTV infection in vivo. More-
over, MyD88 in hematopoietic cells is essential for resistance
to mousepox.
Infected Inflammatory Monocytes Are Responsible for
Most of the IFN-I Expressed in the dLNs
In several infection models, plasmacytoid dendritic cells (pDCs)
sense infection through TLR9-MyD88 to become the major pro-
ducers of IFN-I (Colonna et al., 2004; Ito et al., 2005). However,
B6 mice depleted of pDCs with the anti-BST2 mAb 927 (Fig-
ure S1A; Blasius et al., 2006) did not differ significantly from
mice treated with control rat IgG in terms of IFN-I expression in
the dLNs at 2.5 dpi (Figure S1B) and of virus loads in the liver
at 7 dpi (Figure S1C). Consistent with these findings, they did
not show any differences in IFN-I expression in the dLNs at 5
dpi and were resistant to lethal mousepox (not shown). Hence,
pDCs are neither the major producers of IFN-I in the dLNs nor
essential for the resistance of B6 mice to mousepox after infec-
tion with ECTV.
Having found that pDCs are not themajor producers of IFN-I in
the dLNs, we attempted to identify the relevant bone-marrow-
derived cells. In initial experiments analyzing the response to
ECTV in the dLNs at 2.5 dpi, we found an increase in CD11b+
cells that also stained with the anti-Ly6C+GmAb Gr1 (Figure 3A,
gate 1) but at lower levels than typical neutrophils (Figure 3A,
gate 2). The absolute number of gate 1 cells peaked in the
dLNs at 3 dpi (Figure 3B). At 5 dpi they had disappeared, most
likely because at this time after infection the dLNs were almost
acellular (not shown). The cells in gate 1 stained with anti-Ly6C
but not anti-Ly6G mAbs (Figure 3C) and were mononuclear (Fig-
ure 3D), indicating that they were not neutrophils. These cells
were MHC II+ and CD11c+ and expressed the monocyte or
macrophage markers CD64 and F4/80 (Gautier et al., 2012) but
were negative or low for the DC core markers CD26, CD117 (c-
Kit), CD135 (Flt3), and BTLA (Figure 3E; Miller et al., 2012), sug-
gesting that they were inflammatory monocytes (iMos) and not
dendritic cells (DCs). Hereafter, we will refer to the cells in gate
1 as iMos.
Using ECTV-EGFP (Fang et al., 2008), we found that in the
dLNs, ECTV preferentially infected myeloid and B cells (Fig-
ure S2), which are mostly MHC II+. To identify the cell types
that produce IFN-I in the dLNs, we determined IFN-I expression
in sorted cell populations from the dLNs at 2.5 dpi. We found that
IFN-I expression segregated with MHC II+ cells and, among
these cells, iMos but not B cells expressed IFN-I (Figure 3F).
We also sorted iMos, B cells, and the rest of the cells in the
dLNs of ECTV-infected mice at 2.5 dpi. As compared to the
rest of the cells, iMos expressed significantly higher levels ofc.
 F4/80CD64
CD26 CD117 CD135 BTLA
E
Un
inf
ec
ted
un
so
rte
d
all
 M
HC
 II
+
all
 M
HC
 II
-
iM
o
B c
ell
s
0
2
4
6
8
IFNα5
eipo
C
s
rep
Rgn
01x(
A
N
3 )
IFNβ
F
ECTV (2 dpi)
R
el
at
iv
e 
to
 N
ai
ve
IFNα5IFNβ
R
el
at
iv
e 
to
 N
ai
ve *
PB
S 
Cl
od
ron
ate
 
PB
S 
Cl
od
ron
ate
 
G H I
EGFP
C
D
11
b
EGFP- EGFP+
J
R
el
at
iv
e 
to
 N
ai
ve
IFN
α4
IFN
β
IFN
α n
on
-4
0
20
40
60
80
GFP-
GFP+
MHC II CD11c
C
el
l #
dpi
01(
#lle
C
4 )
C
D
11
b
 Ly6C Ly6GGr1
uninfected LN dLN(2 dpi)
Gate 2:
Gate 1: 1.3%Gate 1: 0.1%
CA B Cells in Gate 1 DCells in Gate 1 Cells in Gate 2
0 1 2 3 4
0
2
4
6
*
** **
Un
inf
ec
ted PB
S 
Cl
od
ron
ate
 
iM
o 
in
 d
LN
  (
x1
04
) **
0
2
4
6
0
10
20
30
40
50
**
0
5
10
15
101 103 104102 101 103 104102 101 103 104102 101 103 104102
101 103 104102 101 103 104102 101 103 104102
101 103 104102 101 103 104102 101 103 104102
101 103 104102
10
1
10
3
10
4
10
2
101 103 104102
101 103 104102
1
0
1
1
0
3
1
0
4
1
0
2
100
80
60
40
20
C
el
l #
100
80
60
40
20
C
el
l #
100
80
60
40
20
Figure 3. Infected Inflammatory Monocytes Are Responsible for Most of the IFN-I Expressed in the dLNs
(A) Representative flow cytometry plots depicting the gating and frequency of a population of CD11b+Gr1+ (gate 1) cells in the popliteal LNs of an uninfected
mouse and in the dLNs of an infectedmouse at 2.5 dpi with ECTV. A second gate (gate 2) with higher expression of the molecules (presumably neutrophils) is also
shown.
(B) Number of cells in gate 1 at the indicated dpi. p values are compared to day 0. Data are displayed as themean ± SEM of fivemice per group in one experiment,
which is representative of three similar experiments.
(C) At 2.5 dpi, gate 1 cells were analyzed for expression of the indicatedmolecules using specificmAbs (shaded) or isotype Ab as control (open). Data displayed as
a representative sample of five mice per group. The experiment was repeated three times.
(D) At 2.5 dpi, gate 1 (left) and gate 2 (right) cells were sorted and stained with Giemsa. Data are representative of two experiments each with pools of fivemice per
group.
(E) As in (C). Gate 1 cells are now referred as inflammatory monocytes (iMos).
(F) IFN-I expression in unsorted cells or the indicated sorted cells from uninfected LNs or dLNs at 2.5 dpi. Data, displayed asmean ± SEM of pooled cells from five
mice per group, are representative of two similar experiments. p values are not shown because the data correspond to two technical replicates.
(G) Number of iMos in the LNs of uninfected mice and at 2.5 dpi in the dLNs of mice treated intravenously with liposomes filled with PBS as a control or with
clodronate to deplete monocytes andmacrophages. Data, displayed as individual mice andmean ± SEM, correspond to an experiment with four mice per group,
which is representative of two similar experiments.
(H) IFN-I expression at 2.5 dpi in the dLNs of mice receiving PBS or clodronate liposomes i.v. Data, shown asmean ± SEM, correspond to an experiment with five
mice per group, which is representative of two similar experiments.
(I) Representative flow cytometry plot depicting EGFP and CD11b expression in the iMo gate from the dLNs at 2.5 dpi with ECTV-EGFP. EGFP (uninfected) and
EGFP+ (infected).
(J) IFN-I expression in sorted EGFP or EGFP+ iMos gated as in (I). Data are displayed asmean ± SEM of pooled cells from fivemice per group in one experiment,
which is representative of two similar experiments. p values are not shown because the data correspond to two technical replicates.
For all, *p < 0.05; **p < 0.01.several innate immune genes involved in IFN-I expression
including Tlr9, Myd88, M21d1 (which encodes cGAS), and Irf7
but not Tmem173, Irf3, and Nfkb1. On the other side, B cells ex-Immpressed significantly higher levels of only Tlr9 and Irf3 (Figure S2).
As compared to controls, significantly fewer iMos were recruited
to the dLNs of mice that had been inoculated intravenously withunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inc. 1151
liposomes filled with clodronate, known to deplete monocytes
and macrophages in vivo (Figure 3G; Seiler et al., 1997; Van
Rooijen, 1989). Moreover, mice treated with clodronate lipo-
somes expressed significantly less IFN-I than those treated
with PBS liposomes (Figure 3H).
Next, we infected mice with ECTV-EGFP and sorted infected
(EGFP+) and uninfected (EGFP) iMos from dLNs at 2.5 dpi
(Figure 3I). We found that EGFP+ iMos expressed significantly
more IFN-I than EGFP iMos (Figure 3J). Thus, infected iMos
are the major producers of IFN-I in the dLNs of mice infected
with ECTV.
The Recruitment of iMos Needs Extrinsic MyD88
whereas the Efficient Expression of IFN-I Requires
Intrinsic STING
We next sought to identify the molecular mechanisms respon-
sible for iMo recruitment. Compared to B6 mice, significantly
fewer iMos were recruited into the dLNs of Tlr9/ and
Myd88/ but not Tmem173gt mice (Figure 4A). Hence,
the recruitment of iMos into the dLNs requires TLR9-MyD88
but not STING. We next asked whether iMos require intrinsic
and/or extrinsic MyD88 to accumulate in the dLNs and/or ex-
press IFN-I. For this, we used mixed bone marrow chimeras
made with a 1:1 mixture of bone marrow from B6 congenic
CD45.1+ (WT) and CD45.2+ Myd88/ bone marrow transferred
into WT mice (henceforth, WT+Myd88/ chimeras; Figure 4B).
At 2.5 dpi, WT and Myd88/ iMos accumulated in the dLNs of
WT+Myd88/ chimeras at similar frequencies (Figures 4C and
4D). Of note, in WT+Myd88/ chimeras infected with ECTV-
EGFP, EGFP+Myd88/ and EGFP+WT iMos expressed similar
levels of IFN-I (Figure 4E). Conversely, in WT+Tmem173gt chi-
meras, EGFP+ Tmem173gt iMos expressed significantly less
IFN-I than EGFP+ WT iMos (Figure 4F). Hence, to accumulate
in the dLNs or produce IFN-I, iMos do not require intrinsic
MyD88. However, they need intrinsic functional STING to effi-
ciently express IFN-I.
The Accumulation of iMos in the dLNs Requires TLR9
and MyD88 Expression in Chemokine-Producing
CD11c+ Cells
Next, we crossed mice carrying Cre recombinase in different
cell types with mice carrying floxed alleles of Myd88
(Myd88fl/fl) or Tlr9 (Tlr9fl/fl) to specifically eliminate MyD88
and TLR9 in cells of interest. Mice without Myd88 in hepato-
cytes (Alb-Cre Myd88fl/fl, selected as controls because hepa-
tocytes are late targets of ECTV infection) or in monocytes
and macrophages (Lyz2-Cre Myd88fl/fl) survived the infection.
Conversely, most Vav1-Cre Tlr9fl/fl mice and all Vav1-Cre
Myd88fl/fl mice, which are deficient in TLR9 and Myd88,
respectively, in all hematopoietic cells, succumbed to mouse-
pox. Similarly, most Itgax-Cre Tlr9fl/fl and all Itgax-Cre
Myd88fl/fl, which lack TLR9 and MyD88, respectively, in
CD11c+ cells, also died from mousepox (Figure 5A). Concor-
dantly, iMos accumulated efficiently in the dLNs of Alb-Cre
Myd88fl/fl and Lyz2-Cre Myd88fl/fl mice but poorly in the
dLNs of Vav1-Cre Myd88fl/fl, Itgax-Cre Myd88fl/fl, Vav1-Cre
Tlr9fl/fl, and Itgax-Cre Tlr9fl/fl mice (Figures 5B and 5C). More-
over, Vav1-Cre Myd88fl/fl and Itgax-Cre Myd88fl/fl mice ex-
pressed significantly lower levels of IFN-I in the dLNs than1152 Immunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier InAlb-Cre Myd88fl/fl mice, whereas normal levels were detected
in Lyz2-Cre Myd88fl/fl mice (Figure 5D).
We next sought to understand why extrinsic TLR9 and MyD88
are required to recruit iMos to the dLNs. Because chemokine
gradients regulate leukocyte migration (Griffith et al., 2014), we
used RT-qPCR to determine which chemokines were upregu-
lated in the dLNs at 1 dpi in a TLR9- and MyD88-dependent
manner. We found that CCL2 and CCL7 (Figure 5E), which are li-
gands for the chemokine receptor CCR2 and known to be
involved in the recruitment of iMos to inflamed tissues (Griffith
et al., 2014), were upregulated in B6 but not in Tlr9/, Vav1-
Cre+ Myd88fl/fl, Itgax-Cre+ Myd88fl/fl, Vav1-Cre+ Tlr9fl/fl, and
Itgax-Cre+ Tlr9fl/fl mice. This suggested that CCL2 and CCL7,
induced by TLR9 and MyD88 signaling, might be involved in the
recruitment of iMos to the dLNs. In agreement, mice deficient in
CCL7 (Ccl7/) recruited significantly fewer iMos to the dLNs
than B6 mice upon ECTV infection. The impaired recruitment of
iMos in Ccl7/ mice was exacerbated by treatment with the
CCR2 antagonist RS102895 (Figure 5F; Giunti et al., 2006). These
data suggest that the efficient recruitment of iMos to the dLNs re-
quires expression of CCR2-binding chemokines and that this
expression requires intrinsic TLR9 and MyD88 in CD11c+ cells.
Of note, iMos were still the key cells that expressed IFN-I in
RS102895-treated Ccl7/ mice (Figure S3A). Yet, despite the
reduced number of iMos, we did not detect significant differences
in the levels of IFN-I in the dLNs of B6 and RS102895-treated
Ccl7/ mice (not shown). Although we do not know the reason
for the lack of significant differences, we have found that
RS102895-treated Ccl7/ mice have significantly higher virus
loads thanB6mice in the dLNs at 2.5 dpi and iMos are still thema-
jor producers of IFN-I (Figure S3B). Perhaps this increase in virus
loads somehow compensates for the decrease in iMos.
IRF7 Is Required for the Efficient Recruitment of iMos
and IFN-I Expression in the dLNs
Next, we sought to identify the transcription factors downstream
of TLR9-MyD88 and STING necessary for the accumulation of
iMos in the dLNs and for their expression of IFN-I. It is well estab-
lished that TLR9-MyD88 signaling activates the transcription
factors IRF7 and NF-kB (Orzalli and Knipe, 2014), whereas
STING mainly activates IRF3 and NF-kB (Wu and Chen, 2014)
but can also activate IRF7 (Ishikawa and Barber, 2008). As we
previously reported, B6 mice that lack the transcription factor
IRF7 (Irf7/) are susceptible to mousepox whereas B6 mice
that lack IRF3 (Irf3/) are resistant (Rubio et al., 2013). Similar
to Myd88/ mice, Irf7/ mice were more susceptible to
ECTV infection than STING-deficient mice because 100% of
Irf7/ and Myd88/ but only 80% of Tmem173gt mice suc-
cumbed to mousepox (not shown). Also, the livers of Irf7/
mice showed severe pathology as determined by histology
and immunohistochemistry (Figure 6A). Accordingly, the virus
titers in the livers of Irf7/ mice were as high as those in
Myd88/ mice (Figure 6B). Consistent with being downstream
of MyD88, the virus titers in Irf7/ mice were similar to those
in Myd88/ mice but significantly higher than in Tmem173gt
mice (p < 0.01). Also phenocopying MyD88 deficiency, the
recruitment of iMos to the dLNs of Irf7/ mice was impaired
(Figure 6C). Furthermore, the expression of IFN-I in the dLNs of
Irf7/ mice was as low as in the dLNs of Myd88/ mice andc.
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Figure 4. The Recruitment of iMos Needs Extrinsic MyD88 whereas the Efficient Expression of IFN-I Requires Intrinsic STING
(A) The indicated mice were infected with ECTV and at 2.5 dpi, their dLNs were analyzed for the presence of iMos. Representative flow cytometry plots (left) and
the calculated numbers of iMos (right) are shown. Data, shown as individual mice andmean ± SEM, correspond to an experiment with five mice per group, which
is representative of two similar experiments.
(B) Diagram of the experiments in (C)–(F).
(C) Representative flow cytometry plots of the dLNs and non-dLNs of WT+Myd88/ chimeras at 2.5 dpi. The plots on the left show CD11b and Gr1 staining with
the iMo gates marked. The plots on the right show the expression of CD45.2 and CD11c in the iMo gates. The gates for mutant (CD45.2+) andWT (CD45.2) iMos
are shown.
(D) Ratio of WT/Myd88/ iMos in the dLNs of WT+Myd88/ chimeras. Data, shown as individual mice and mean ± SEM, correspond to an experiment with four
mice per group, which is representative of two similar experiments.
(E) Representative flow cytometry plot for EGFP andCD45.2 expression in gated iMos from dLNs ofWT+Myd88/ chimeras at 2.5 dpi with ECTV-EGFP (left) and
IFN-I expression in the sorted EGFP+ WT and EGFP+ Myd88/ iMos (right). Data are for pooled cells from five mice per group and representative of two similar
experiments. Means ± SEM of three technical replicates are shown.
(F) As in (E) but with cells from WT+Tmem173gt chimeras.
For all, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.significantly lower than in the dLNs of Tmem173gt mice (Fig-
ure 6D). In addition, Irf7/ mice did not upregulate the expres-
sion of Ccl2 and Ccl7 in the dLNs (Figure 6E). Together, these
data suggest that the expression of the chemokines that recruit
iMos to the dLNs requires the transcription factor IRF7 down-
stream of TLR9-MyD88.ImmInflammatory Monocytes Require Intrinsic STING-IRF7
and STING-NF-kB to Express IFN-a and IFN-b,
Respectively
We next determined whether iMos require intrinsic IRF7 to ex-
press IFN-a and IFN-b. We found that infected iMos obtained
at 2.5 dpi with ECTV-EGFP from the dLNs of Tmem173gt miceunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inc. 1153
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Figure 5. The Accumulation of iMos in the dLNs Requires TLR9 and MyD88 in Chemokine-Producing CD11c+ Cells
(A) Survival of the indicated mice to ECTV infection. Data correspond to one experiment with five mice per group and is representative of three similar experi-
ments. p values are compared to Alb-Cre Myd88fl/fl mice.
(B) Calculated number of iMos in the dLNs of the indicated mice at 2.5 dpi. Data, displayed as individual mice with mean ± SEM, correspond to one experiment
with five mice per group, which is representative of three similar experiments.
(C) As in (B), but for indicated mice.
(D) Expression of IFN-I in the dLNs of the indicatedmice at 2.5 dpi. p values are compared toAlb-CreMyd88fl/fl mice. Data, displayed asmean ± SEM, correspond
to one experiment with five mice per group, which is representative of three similar experiments.
(E) Ccl2 and Ccl7 expression in the dLNs at 1 dpi. p values are compared to naive B6 mice (not shown) and are similar for Ccl2 and Ccl7. Data displayed as in (E).
(F) As in (B), but for indicated mice.
For all, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.expressed IFN-b inefficiently, whereas those from Irf3/ and
Irf7/ mice expressed as much IFN-b as iMos from WT B6
mice. In contrast, infected iMos from the dLNs of Irf3/ mice
expressed as much ‘‘early’’ IFN-a4 and ‘‘late’’ IFN-a5 as those
from WT mice, but those from Tmem173gt and the few present
in Irf7/ mice expressed significantly less (Figure 7A). There-
fore, the signaling pathways for IFN-a and IFN-b expression
diverge downstream of STING, with IRF7 being required for effi-
cient IFN-a but not IFN-b expression.
Givenourpreviousfindingofacrosstalkbetween theNF-kBand
IFN-I pathways during ECTV infection (Rubio et al., 2013), we
speculated that in ECTV-infected iMos, NF-kB is the transcription
factor downstreamof STING that is responsible for the expression
of IFN-b. However, we were unable to directly test this idea in
Nfkb1/ mice, because these mice lack popliteal lymph nodes
(Rubio et al., 2013). Thus, we produced WT+Nfkb1/ and also1154 Immunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier InWT+Irf7/ bonemarrow chimeras (Figures 7B–7E). In both types
of chimeras, WT and mutant iMos accumulated in the dLNs at
similar frequencies (not shown). Hence, iMos do not need intrinsic
NF-kB or IRF7 to accumulate in the dLNs. When tested for IFN-I
expression, Irf7/ iMos expressed significantly less early IFN-
a4 and late IFN-a5 than WT iMos but the levels of early IFN-b
were similar. On the other hand, Nfkb1/ iMos expressed as
much early and late IFN-a but significantly less IFN-b than WT
iMos. Thus, in ECTV-infected iMos, efficient transcription of early
and late IFN-a requires IRF7 whereas the expression of IFN-b is
mostly dependent on NF-kB transcription.
DISCUSSION
We have studied how different pathways of pathogen sensing
and cell types contribute to IFN-I expression and resistance toc.
A B C D E
Figure 6. IRF7 Is Required for the Efficient Recruitment of iMos and IFN-I Expression in the dLNs
(A) Representative liver sections from Irf7/mice at 7 dpi stained with H&E (top) or with anti-ECTV Ab (bottom). The experiment was performed three times with
four or five mice per group with similar results.
(B) ECTV titers in the liver of the indicated mice at 7 dpi. Data, displayed as individual mice with mean ± SEM, correspond to one experiment with four or five mice
per group, which is representative of three similar experiments.
(C) Numbers of iMos in the dLNs of the indicated mice at 2.5 dpi. Data as in (B).
(D) IFN-I in the dLNs of the indicated mice at 2.5 dpi expressed as percent of the values for the same interferon in infected B6 mice. Data, displayed as
mean ± SEM, correspond to one experiment with five mice per group, which is representative of three similar experiments.
(E) Expression of the indicated chemokines in the dLNs of the indicated mice at 1 dpi. Data as in (D).
For all, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.a highly lethal infection caused by ECTV, a DNA virus of the
genus Orthopoxvirus that also includes variola virus (VARV, the
virus that causes smallpox) and vaccinia virus (VACV, the small-
pox vaccine). For this purpose, we have focused on the dLNs
because of its critical role in restricting viral spread (Fang et al.,
2008; Junt et al., 2007; Kastenmu¨ller et al., 2012).
The most important aspect of our work is the finding that the
DNA-sensing pathways TLR9-MyD88-IRF7 and STING-IRF7-
NF-kB are essential for efficient IFN-I production and resistance
to mousepox but that their respective roles in IFN-I expression
are very different: the TLR9-MyD88-IRF7 pathway is required
in CD11c+ cells for the expression in the dLNs of CCR2 li-
gands—and probably other pro-inflammatory molecules neces-
sary for the efficient recruitment of iMos to the dLNs—whereas
the STING-IRF7 and STING-NF-kB axes are needed for IFN-I
expression in infected iMos. That STING is necessary for IFN-I
expression is consistent with the recent finding that STING is
required for IFN-I expression in mouse cDCs infected with modi-
fied VACV strain Ankara (MVA) (Dai et al., 2014). Although we
have ruled out DAI as the critical DNA sensor, we have not yet
identified which is the receptor upstream of STING that senses
ECTV to drive IFN-I expression. We hypothesize the key sensor
is cGAS, because cGAS-STING is used by mouse cDCs (Dai
et al., 2014; Li et al., 2013), mouse macrophages and fibroblasts
(Li et al., 2013), and human embryonic kidney 293 cells (Ablasser
et al., 2013) to produce IFN-I in vitro after infection withWT VACV
or MVA.
We have also ruled out TRIF and MAVS as key players in IFN-I
expression and resistance to mousepox after ECTV infection.
That TRIF is not essential is not surprising because TLR9 uses
MyD88 but not TRIF as the adaptor, and because TLR9 is the
only TLR required for resistance to mousepox (Rubio et al.,
2013; Samuelsson et al., 2008; Sutherland et al., 2011). How-
ever, the finding that MAVS has no role is unexpected, because
MAVS transduces signals from RNA-sensing RLRs, and it has
been shown that in cultured cells, VACV, which is very similarImmto ECTV, produces RNA species that can activate these path-
ways and induce IFN-I expression (Myskiw et al., 2011; Pichlmair
et al., 2009).
We also found that pDCs are not required for IFN-I expres-
sion or survival to ECTV infection. pDCs, which express RNA-
and DNA-sensing TLR7, TLR8, and TLR9, have been touted
as professional IFN-I producers (Gilliet et al., 2008). However,
they have been proven not essential for IFN-I expression and/
or resistance to infection in various infectious mouse models
including vesicular stomatitis virus, influenza virus, mouse cyto-
megalovirus, and lymphocytic choriomeningitis virus (Reizis
et al., 2011). Furthermore, it has been shown that pDCs
contribute to IFN-I expression to systemic but not local infec-
tion with HSV-1, another large DNA virus (Swiecki et al.,
2013). That pDCs are not essential for resistance to ECTV is
in contrast to the findings of Tahiliani et al. (2013), who recently
reported that mice depleted of pDCs succumbed to mousepox.
Although that study did not examine IFN-I expression after
infection, we attribute this discrepancy to differences in anti-
BST2 mAb clones and doses between our study and theirs
and the possible depletion of other cell types by this type of
mAbs (Swiecki and Colonna, 2010).
The finding that the cells that exclusively express IFN-I in the
dLNs are infected iMos is novel and unexpected because these
cells are not considered professional IFN-I producers. Neverthe-
less, it has been shown that Ly6C+ iMos use TLR2 to produce
IFN-I during VACV infection (Barbalat et al., 2009) and
that iMos produce IFN-b in response to Toxoplasma gondii
(Han et al., 2014). Moreover, other myeloid cells have been found
to produce IFN-I. For example, conventional DCs (cDCs) pro-
duce IFN-I in response to lymphocytic choriomeningitis virus
(Diebold et al., 2003), reovirus (Johansson et al., 2007), and rota-
virus (Lopez-Guerrero et al., 2010) in vivo. Also, cDCs and mac-
rophages express IFN-I in response to herpes simplex virus
(Rasmussen et al., 2007) and alveolar macrophages in response
to Newcastle disease virus (Kumagai et al., 2007). In culture,unity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inc. 1155
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Figure 7. Inflammatory Monocytes Require Intrinsic STING-IRF7
and STING-NF-kB to Express IFN-a and IFN-b, Respectively
(A) Expression of IFN-I in sorted EGFP+ iMos sorted from the dLNs of the
indicatedmice at 2.5 dpi. Data, displayed asmean ± SEM fromone experiment
representative of three, correspond to pooled cells from five mice per group
and three technical replicates.
(B) Representative flow cytometry plots of gated iMos from the dLNs at 2.5 dpi
of WT+ Irf7/ chimeras showing CD45.1 and EGFP expression (left).
(C) IFN-I expression in sorted infected (EGFP+) WT (CD45.1+) and Irf7/
(CD45.1) iMos from WT+Irf7/ chimeras as identified in (B). Data, displayed
as mean ± SEM from one experiment representative of three, correspond to
pooled cells from five mice per group and three technical replicates.
(D) As in (B) but for WT+Nfkb1/ chimeras.
(E) As in (C) but for WT+Nfkb1/ chimeras.
For all, *p < 0.05; **p < 0.01; ***p < 0.001.influenza-virus-infected humanmonocyte-derived DCs also pro-
duce IFN-I (Cao et al., 2012).
The discoveries that iMos express IFN-I only if they are in-
fected and that STING is the critical adaptor are internally consis-
tent. STING is used by PRRs that recognize the presence of
PAMPs in the cytosol, which indicates an ongoing infection.
Interestingly, although B cells constitute the vast majority of in-
fected cells in the dLNs, they failed to express IFN-I. A possible1156 Immunity 43, 1148–1159, December 15, 2015 ª2015 Elsevier Inreason is that when compared to monocytes, they express low
levels of IRF7 and the cytosolic DNA sensors IFI16 (Ifi204) and
cGAS (E330016A19Rik) as indicated in the Immgen database
(http://www.immgen.org) and as suggested by our own RT-
qPCR analysis.
The identity and residence of the CD11c+ cells in which the
TLR9-MyD88-IRF7 pathway is needed for CCR2-ligand expres-
sion still needs to be elucidated. One possibility is that they are
Langerhans cells or dermal DCs that reside in the footpad and
migrate to the dLNs in a TLR9-MyD88-dependent manner (Mar-
tı´n-Fontecha et al., 2009). It is also possible that these cells are
DCs that reside in the subcapsular space that have recently
shown to be the first to capture particulate antigens in the dLNs
(Radtke et al., 2015). We speculate that CD11c+ cells need
TLR9-MyD88 intrinsically to express the CCR2 ligands and prob-
ably other inflammatory cytokines that are required for iMomigra-
tion. However, it remains possible that the role of TLR9-MyD88 in
CD11c+ cells is also indirect for this function. Regardless of this,
iMos migrate to the dLNs in response to signals that depend on
TLR9-MyD88 in CD11c+ cells. After migrating to the dLNs, iMos
become targets of infection and, consequently, the major pro-
ducers of IFN-I in the dLNs. Notably, iMos do not need intrinsic
MyD88 to migrate to the dLNs or to produce IFN-I; instead, they
rely on intrinsic STING-IRF7 and STING-NF-kB signaling for
expression of IFN-a and IFN-b, respectively.
The most frequently studied IRF downstream of STING is IRF3
(Wu and Chen, 2014). Therefore, it might be surprising that the
expression of IFN-I is not altered in Irf3/ mice. However, it
has been shown that STING can directly activate IRF7 (Ishikawa
and Barber, 2008). Moreover, IRF7 is expressed at much higher
levels than IRF3 in most myeloid cells (http://www.immgen.org),
and in our own experiments, IRF7 but not IRF3 was expressed at
higher levels in iMos than in other cells. This suggests that in
iMos, STING-IRF7 signaling makes IRF3 redundant.
Our experiments suggest that iMos have additional pathways
for IFN-I expression because infected iMos deficient in Irf7/
and Tmem173gt expressed detectable (albeit significantly
reduced) IFN-I. Although insufficient to protect most mice from
lethal mousepox, these alternate pathways might explain why
Tmem173gt mice, which recruit iMos to the dLNs, are less sus-
ceptible than MyD88 and IRF7 mice, which do not recruit iMos
to the dLNs.
We also found that the expression of IFN-b in iMos is strictly
dependent on NF-kB, even though the ifnb1 enhancer has bind-
ing sites for NF-kB, IRF3, and IRF7 (Honda et al., 2005). Merika
et al. (1998) have shown that NF-kB p65 is needed for the initial
capture and stabilization of CBP-p300 at the enhanceosome, so
probably this role for NF-kB is more critical in driving IFN-b
expression in iMos than it is in MEFs, where NF-kB appears
largely dispensable for virus-driven IFN-b expression (Balachan-
dran and Beg, 2011; Wang et al., 2007).
In summary, we have identified iMos as the cell type critical for
IFN-I production in the dLNs after infection with a poxvirus
through its biological route in its natural host. Moreover, we
show that two DNA-sensing pathways, both traditionally associ-
ated with a direct role in IFN-I expression, play distinct but
sequentially roles in different cell types: the TLR9-MyD88-IRF7
pathway functions in CD11c+ cells to recruit iMos to the dLNs
and the STING-IRF7 and STING-NF-kB pathways are directlyc.
responsible for IFN-I production after iMo infection. Together,
these results provide important insights into how distinct path-
ogen-sensing mechanisms co-operate to recognize and limit
pathogen spread in vivo.
EXPERIMENTAL PROCEDURES
Mice and Animal Experiments
All the procedures involvingmice were carried out in strict accordancewith the
recommendations in the Guide for the Care and Use of Laboratory Animals of
the NIH. All protocols were approved by Fox Chase Cancer Center’s (FCCC)
Institutional Animal Care andUse Committee. B6 (C57BL/6, CD45.2+; Taconic)
and B6-LY5.1/Cr (B6-CD45.1, CD45.1+; NCI-Charles River) mice were pur-
chased at 6–8 weeks of age. All other mice, in a B6 background, were bred
at FCCC from original breeders obtained from different sources and used at
an age of 6–16 weeks. Vav1-Cre (B6.Cg-Tg(Vav1-cre)A2Kio/J), Alb-Cre
(B6.Cg-Tg(Alb-cre)21Man/J), Lyz2-Cre (B6.129P2-Lyz2tm1(cre)Ifo/J), Itgax-Cre
(B6.Cg-Tg(Itgax-cre)1-1Reiz/J), Ccl7/ (B6.129S4-Ccl7tm1ifc/J), Nfkb1/
(B6.Cg-Nfkb1tm1Bal/J),Myd88fl/fl (B6.129P2(SJL)-Myd88tm1Defr/J), Tmem173gt
(C57BL/6J-Tmem173gt/J), Tlr2/ (B6.129-Tlr2tm1Kir/J), and Il1r/ (B6.129S7-
Il1r1tm1Imx/J) mice were originally purchased from Jackson Laboratories.
B6.129-Tlr9tm1Aki/Obs (Tlr9/) and B6.129-Myd88tm1Aki/Obs (Myd88/)
mice were produced by Dr. S. Akira (Osaka University, Japan) (Adachi et al.,
1998; Hemmi et al., 2000) and generously provided by Dr. Robert Finberg (Uni-
versity of Massachusetts, Worcester, MA). Irf7/ (B6.129P2-Irf7tm1Ttg/
TtgRbrc), Irf3/ (B6;129S6-Irf3tm1Ttg/TtgRbrc), and B6.129B6-Mavstm1Tsse
were from Riken Bioresource Center (Tsukuba, Japan). Ifnar1/ mice back-
crossed to B6 (Moltedo et al., 2011) were a gift from Dr. ThomasMoran (Mount
Sinai School of Medicine, New York, NY), and Zbp1/mice (Ishii et al., 2008)
were a gift from Dr. S. Akira. Tlr9fl/fl mice were produced in the M.S. laboratory
and will be described in detail elsewhere. In brief, LoxP sites were inserted
flanking exon 2, which contains virtually all of the protein coding sequences,
of TLR9. The mutant allele was created in B6x129 ES cells (line BA1) and
proper targeting was confirmed by PCR, Southern blotting, and sequencing.
Subsequent to germline transmission, the floxed NeoR gene that was part of
the original construct was deleted by breeding to a mouse line that expressed
Cre-recombinase and the proper deletion again confirmed by Southern blot.
The resulting mice were bred to B6 mice for ten generations before crossing
with the Cre-deleter mice obtained from Jackson.
Production of Bone Marrow Chimeric Mice
Bone marrow chimeras were prepared as previously described (Sigal et al.,
1999; Xu et al., 2010) using 5- to 7-week-old mice as donors and recipients.
For mixed bone marrow chimeras, bone marrow cells from the two donor
types were mixed at 1:1 ratio. Chimeras were used in experiments 6–8 weeks
after reconstitution.
Viruses and Infection
Virus stocks, including ECTVMoscow strain (ATCCVR-1374) and ECTV-EGFP
(Fang et al., 2008), were propagated in tissue culture as previously described
(Xu et al., 2008). Mice were infected in the footpad with 3,000 plaque forming
units (PFUs) ECTV WT or ECTV-EGFP as indicated. For the determination of
survival, the mice were monitored daily. To avoid unnecessary suffering,
mice were euthanized and counted as dead when imminent death was certain
as determined by lack of activity and unresponsiveness to touch. For virus ti-
ters, the entire spleen or portions of the liver were homogenized in PBS using a
Tissue Lyser (QIAGEN). Virus titers were determined on BS-C-1 cells as before
(Xu et al., 2008).
Cell Depletions
To deplete pDCs, B6mice were injected with 500 mg rat mAb 927 or control rat
IgG (Blasius et al., 2006) 1 day before and 1 day after infection with ECTV. Effi-
cient depletion of pDCs was confirmed by flow cytometry using mAbs B220
and 400c (anti-Siglec-H) on inguinal LNs and spleen at 2 days after the second
depletion. To deplete monocytes/macrophages, mice received 200 ml clodro-
nate-liposomes diluted to 5 mg/ml clodronate or control PBS-liposomes intra-
venously 2 days before infection.ImmFlow Cytometry
Flow cytometry was performed as previously described (Xu et al., 2008). mAbs
to CD3 (145-2C11), CD4 (GK1.5), CD8a (53–6.7), CD11c (N418), IFN-g
(XMG1.2), CD64 (X54-5/7.1), F4/80 (BM8), CD135 (Flt3, clone A2F10),
CD117 (c-Kit, clone 2B8), CD272 (6A6), CD26 (H194-112), IA/IE (M5/
114.15.2), Ly-6G (IA8), Ly-6C (HK1.4), B220 (RA3-6B2), CD317 (BST2,
PDCA-1, Clone 927), and CXCL9 (MIG-2F5.5) were from Biolegend. mAbs to
CD45.1 (A20), CD45.2 (104), Ly-6G and Ly-6C (Gr-1, Clone RB6-8C5), B220
(RA3-6B2), and CD11b (H194-112) were from BD Biosciences. mAb to Si-
glec-H (eBio440c) was from eBioscience.
To obtain single-cell suspensions, LNs were minced and dissociated in Lib-
erase TM (1.67 Wu¨nsch units/ml) and DNase I (0.2 mg/ml; Roche Diagnostics)
in PBS with 25 mM of HEPES for 30 min at 37C. Liberase digestion was fol-
lowed by mechanical disruption of the tissue through a 70-mm filter. Cells
were washed once with complete RPMI medium before surface staining. For
analysis, samples were acquired using a BD LSR II flow cytometer (BD Biosci-
ences), and data were analyzed with FlowJo software (TreeStar). For cell sort-
ing, samples were acquired with a BD FACSAria III sorter (BD Biosciences).
Histopathology
Livers were harvested and fixedwith formalin and stainedwith H&E or with rab-
bit anti-EVM135 as previously described (Xu et al., 2012). Sorted cells were
stained using a standard Wright-Giemsa protocol.
RNA Preparation and RT-qPCR
Total RNA from LNs was obtained with the RNeasy Mini Kit (QIAGEN) as pre-
viously described (Rubio et al., 2013; Xu et al., 2012). Total RNA from sorted
cells (104–105 cells) was extracted with Trizol reagent (Life Technologies) ac-
cording to the manufacturer’s instructions. In brief, 104 cells were added
into 1 ml of Trizol. When precipitating RNA, 10 mg of RNase-free glycogen (In-
vitrogen) was added to the aqueous phase as a carrier. First-strand cDNA was
synthesized with High Capacity cDNA Reverse Transcription Kit (Lift Technol-
ogies). qPCR was performed as before (Rubio et al., 2013; Xu et al., 2012)
using probes from the Universal Library (Roche) and the oligonucleotides sug-
gested by the manufacturer’s software.
Statistics
Data were analyzed with Prism 6 software (GraphPad Software). For survival
we used the Log-rank (Mantel-Cox). For other experiments, ANOVA with Tu-
key correction for multiple comparisons or Student’s t test were used as appli-
cable. In all figures, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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